SCHEMBL5203515

SCHEMBL5203515

COc1ccccc1C(C)(C)CC(O)(CCc1ccccc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 7/20 0.54
NR3C1 P04150 3/20 0.51
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TAAR1 Q96RJ0 2/20 0.41
NR3C2 P08235 1/20 0.41
HPGD P15428 1/20 0.41
PGR P06401 1/20 0.40
GPR52 Q9Y2T5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3656627 0.88 NR3C1 (0.68) NR3C1NR3C2PGR
SCHEMBL5207875 0.87 NR3C1 (0.53) SLC13A5NR3C1MEN1KMT2ANR3C2
SCHEMBL5206743 0.86 NR3C1 (0.51) SLC13A5NR3C1MEN1KMT2ANR3C2
SCHEMBL3953659 0.79 NR3C1 (0.62) NR3C1NR3C2PGR
SCHEMBL3650719 0.79 SLC13A5 (0.52) SLC13A5NR3C1MEN1KMT2ANR3C2
SCHEMBL5208004 0.78 HPGD (0.42) SLC13A5NR3C1MEN1KMT2ANR3C2
SCHEMBL3657988 0.77 SLC13A5 (0.50) SLC13A5NR3C1MEN1KMT2APGR
SCHEMBL5208204 0.77 HPGD (0.40) SLC13A5NR3C1MEN1KMT2ANR3C2
SCHEMBL3681311 0.77 NR3C1 (0.50) SLC13A5NR3C1NR3C2PGR
SCHEMBL5208282 0.77 NR3C1 (0.55) NR3C1MEN1KMT2ANR3C2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1467982-B8 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF BOEHRINGER INGELHEIM PHARMA (US) 2007-04-11 EP disclosed
US-7189758-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-03-13 US disclosed
EP-1467982-B1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF BOEHRINGER INGELHEIM PHARMA (US) 2006-11-22 EP disclosed
US-20060030561-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-02-09 US disclosed
US-6960581-B2 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-11-01 US disclosed
EP-1467982-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-10-20 EP disclosed
US-20030232823-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-12-18 US disclosed
WO-2003059899-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232823-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof NR3C1, NR3C2, MC2R SLC13A5 2258/4885NR3C1 1/4885MEN1 1024/4885
US-20060030561-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof NR3C1, MC2R, NR3C2 SLC13A5 2450/4885NR3C1 1/4885MEN1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.